SPI-BIO

SPI-BIO provides services and advice in analysis, pharmacology/pharmacokinetics & develops and markets immunological reagents and kits. SPI-BIO has research and development personnel which have been working over fifteen years with pharmaceutical laboratories in:
- Clinical pharmacology studies (PET, NMR, SPECT) in cardiology, neurology and psychiatry,
- In vivo and in vitro pharmacological assessment of anti-retroviral and immunomodulatory drugs.

- Human Pharmacokinetics and metabolism,
- Bioavailability and Bioequivalence studies,
- Animal Pharmacokinetics,
- In vivo and in vitro metabolism profile.

- development, validation of assays & drug measurement (HPLC, GC, GC/MS, HPLC/MS/MS, RIA, EIA).

Microbiological safety: for anti-retroviral and immunomodulatory drugs

SPI-BIO develops, manufactures and markets reagents and Enzyme-Immunoassay for biological markers and drugs. They are packaged as kit (may be used for pre-clinical and multinational clinical studies).

Activity:

- Contract Research
- Licensing & Business Development
- Research & Development
- Sales & Distribution

Product / Technology type(s) covered:

- Enzymes
- FP (finished products)
- Reagents

Therapeutic targets:

- AIDS
- Allergy
- Alzheimer's Disease
- Diabetes
- Infectious Diseases
- Neurology
- Obesity
- Oncology

Markets Covered

a. HeadQuarter: France

b. Continent(s) active: Europe , North America

c. Countries active: France, Germany, USA, Japan

Corporate data:

Number of Employees: 23

Turnover:

Amount:	Year:	Currency:
2577000	2001	Euro

Year founded: 1991